Michael Fagiola

Title: Michael Fagiola and a Patent for Measuring COPD Biomarkers.

Introduction

Michael Fagiola is an inventor associated with Queens, New York, and St. John’s University. His patent work addresses the measurement of desmosine, a biomarker of elastin degradation, to assess chronic obstructive pulmonary disease (COPD).

Latest Patents

Fagiola’s listed patent, “Method for Measuring COPD Biomarkers,” describes using desmosine to measure the extent and progression of COPD. The method may support COPD screening and provide a real-time indication of how effectively a drug is working. It could offer a more sensitive way to monitor disease and treatment response than pulmonary function studies or computed tomography.

The invention also improves the measurement of desmosine in tissues and body fluids by shortening detection time in liquid chromatography–tandem mass spectrometry (LC-MS-MS) assays. Because it can use LC-MS-MS equipment without modification, the method may be adopted by laboratories that already use the technology, including forensic facilities investigating whether undiagnosed COPD contributed to a death. Fagiola is associated with 1 patent.

Career Highlights

Fagiola’s listed affiliation is St. John’s University. His patent highlights an application of biomarker measurement to disease assessment, treatment monitoring, and forensic analysis.

Collaborations

The provided information identifies Jerome Cantor as Fagiola’s coworker. It does not specify the nature of their collaboration or Cantor’s role in the patent.

Conclusion

Michael Fagiola’s patent focuses on making desmosine measurement faster and more accessible, with potential applications in COPD screening, treatment monitoring, and forensic investigation.